Professional Snapshot
Professional Education
| B.A.: | Oxford University, Zoology |
| Ph.D.: | Harvard University, Biochemistry & Molecular Biology |
| Postdoc.: | University of Geneva, Biologie Moleculaire |
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Web Site Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Pain Therapeutics, Inc. |
Scientific Focus
Research Interests
Our current research is focused on development of novel vectors and strategies for gene therapy. Our primary approach is development of vectors that will integrate at specific sites in the genome. We use the phiC31 phage integrase to mediate genomic integration. We are improving the basic technology, as well as applying it to a diverse set of tissues and diseases.
We are currently delivering integrating plasmid DNA vectors using naked DNA and in vivo and ex vivo electroporation. We are working with animal models for diseases involving blood, eye, muscle, liver, and other tissues.
Publications
- Effect of nuclear localization and hydrodynamic delivery-induced cell division on phiC31 integrase activity. Gene Ther. 2009
- Mutational derivatives of PhiC31 integrase with increased efficiency and specificity. Mol Ther. 2009; (1): 112-20
- Factoring nonviral gene therapy into a cure for hemophilia A. Curr Opin Mol Ther. 2008; (5): 464-70
- Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase. J Neurosci Methods. 2008; (2): 299-305
- Site-specific chromosomal integration mediated by phiC31 integrase. Methods Mol Biol. 2008: 165-73
Help